1
|
Application of the HPLC Method in Parenteral Nutrition Assessment: Stability Studies of Ondansetron. Processes (Basel) 2021. [DOI: 10.3390/pr9030453] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Ondansetron (OND) is a serotonin type 3 receptor antagonist that exhibits antiemetic activity. From the clinical point of view, vomiting and nausea prevention is an important task. Anticancer treatment and recovery impact the patient’s overall state by affecting appetite, well-being, and physical activity, and consequently, nutrition quality. Depending on the patient’s indication and condition, parenteral nutrition is administered to meet full nutritional requirements. In addition, antiemetic drugs can be added to the parenteral nutrition (PN) admixture to treat chemo- or radio-therapy-induced nausea and vomiting. However, adding any medication to the PN admixture can result in the instability of the composition in the overall admixture. This study aimed to develop the HPLC method of determination of OND in Lipoflex special, one of the most popular, ready-to-use PN admixtures. The proposed HPLC method and the sample preparation procedure were suitable for analyzing OND in PN admixture stored under various conditions, such as exposure to sunlight and temperature. It was found that the decomposition of OND during the seven-day storage did not exceed 5% and did not depend on external factors. Based on the conducted research, it is recommended to add OND to Lipoflex special, and it is possible to store such an admixture for seven days.
Collapse
|
2
|
Closset M, Goderniaux N, Colsoul ML, Soumoy L, Bihin B, Jamart J, Odou P, Hecq JD, Galanti L. Long term stability of an admixture of alizapride and ondansetron in 0.9% sodium chloride solution polyolefin bags stored at 5±3°C. J Oncol Pharm Pract 2020; 27:1328-1332. [PMID: 32903143 DOI: 10.1177/1078155220950442] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Patients undergoing chemotherapeutic treatment are currently treated by a concomittent infusion of alizapride and ondansetron. To optimise the procedure and to ensure patients' safety, the admixture could be prepared in advance by the Centralized Intravenous Additive Service (CIVAS) provided that the stability of the mixture has been proven beforhand to reduce nausea and vomiting.Aim of the study: to evaluate the long-term stability of an admixture of alizapride 0.926 mg/l and ondansetron 0.074 mg/ml in 0.9% sodium chloride polyolefin bags stored at 5 ± 3°C. MATERIAL AND METHODS Five polyolefin bags containing 100 ml sodium chloride 0.9% added with 4 ml alizapride (100 mg) and 4 ml ondansetron (8 mg) were prepared in aseptic conditions and stored at 5 ± 3°C for 56 days. Periodically, physical stability tests were performed including: pH measurements, optical density measurements at 350, 410 and 550 nm to track turbidity appearance, visual and microscopical inspections to detect colour changes, precipitation, microaggregates or crystals. The concentrations of the solutions were measured by High Performance Liquid Chromatography coupled with an UV detector. RESULTS There was no change in pH and optical densities during the study period. Visual and microscopical inspections didn't show any change of colour neither precipitation, microaggregate or crystal. The alizapride and ondansetron concentrations remained stable over the study. CONCLUSION The admixture of alizapride and ondansetron in 0.9% sodium chloride solution polyolefin bags is physicochemically stable up to 56 days at 5 ± 3°C. These results support the possibility of preparing the solutions in advance by a CIVAS.
Collapse
Affiliation(s)
- Mélanie Closset
- Medical Laboratory, CHU UCL, Namur, Belgium.,Drug Stability Research Group, CHU UCL, Namur, Belgium
| | - Nicolas Goderniaux
- Medical Laboratory, CHU UCL, Namur, Belgium.,Drug Stability Research Group, CHU UCL, Namur, Belgium
| | - Marie-Lise Colsoul
- Medical Laboratory, CHU UCL, Namur, Belgium.,Drug Stability Research Group, CHU UCL, Namur, Belgium
| | - Laura Soumoy
- Drug Stability Research Group, CHU UCL, Namur, Belgium.,Departement of Pharmacy, CHU UCL, Namur, Belgium
| | - Benoit Bihin
- Drug Stability Research Group, CHU UCL, Namur, Belgium.,Scientific Support Unit, CHU UCL, Namur, Belgium
| | - Jacques Jamart
- Drug Stability Research Group, CHU UCL, Namur, Belgium.,Scientific Support Unit, CHU UCL, Namur, Belgium
| | | | - Jean-Daniel Hecq
- Drug Stability Research Group, CHU UCL, Namur, Belgium.,Departement of Pharmacy, CHU UCL, Namur, Belgium
| | - Laurence Galanti
- Medical Laboratory, CHU UCL, Namur, Belgium.,Drug Stability Research Group, CHU UCL, Namur, Belgium
| |
Collapse
|